靶向溶酶体治疗肿瘤的策略探讨  

Discussion on targeted lysosome therapy for cancer

作　　者：盛基尧 李泳陟 张学文[1] Sheng Ji-yao;Li Yong-zhi;Zhang Xue-wen(Department of Hepatobiliary and Pancreatic Surgery,Jilin University Second Hospital,Changchun,Jilin 130000,China)

机构地区：[1]吉林大学第二医院肝胆胰外科,吉林长春130000

出　　处：《中国现代医学杂志》2023年第19期1-6,共6页China Journal of Modern Medicine

摘　　要：溶酶体是细胞的代谢枢纽和信号平台,更重要的是溶酶体在肿瘤细胞增殖、转移和耐药性等方面都发挥着重要作用。近年来,有关靶向溶酶体治疗肿瘤的研究越来越多,这其中一个重要的机制是当溶酶体受到细胞内外刺激时,会发生溶酶体膜透化,严重的溶酶体膜透化会导致溶酶体依赖性细胞死亡。相较于化疗药物,纳米药物具有更高的特异性和更少的副作用。该文将着重介绍纳米药物通过靶向诱导溶酶体发生溶酶体膜透化治疗肿瘤的进展,旨在为溶酶体相关肿瘤治疗的研究提供参考。Lysosomes serve as critical hubs of cellular metabolism and signaling pathways.Importantly,they play pivotal roles in various aspects of cancer cells,including proliferation,metastasis,and drug resistance.In recent years,research on targeted lysosome therapy for cancer has been on the rise.One significant mechanism involves lysosome membrane permeabilization(LMP)triggered by internal or external stimuli,leading to lysosome-dependent cell death.Compared to conventional chemotherapy,nanomedicines offer higher specificity and fewer side effects.This article will focus on the progress in using nanomedicines to induce lysosomal membrane permeabilization as a targeted therapy for cancer.The aim is to provide insights and references for research in lysosome-related cancer treatments.

关 键 词：溶酶体 纳米药物 溶酶体膜透化 肿瘤治疗 

分 类 号：R730.5[医药卫生—肿瘤]